{
    "pmcid": "11211474",
    "qa_pairs": {
        "What is one of the key mutations in the Spike protein that enhances ACE2 binding and resistance to neutralizing antibodies?": [
            "E484K",
            "L452R",
            "P681R",
            "K417N"
        ],
        "What is the affinity of VHH60 for the SARS-CoV-2 RBD?": [
            "2.56 nM",
            "5.12 nM",
            "1.25 nM",
            "10.34 nM"
        ],
        "What is the origin of the nanobody VHH60 developed to target the SARS-CoV-2 Spike protein?": [
            "It was engineered from the commercialized nanobody caplacizumab.",
            "It was derived from a naturally occurring human antibody.",
            "It was synthesized de novo using computational modeling.",
            "It was isolated from a llama immunized with the Spike protein."
        ],
        "What therapeutic advantage does the multivalent form of VHH60 provide?": [
            "Enhanced potency in blocking ACE2-RBD interactions and inhibiting pseudovirus infection.",
            "Increased stability and longer half-life in the bloodstream.",
            "Reduced immunogenicity and improved safety profile.",
            "Broader spectrum activity against unrelated viral pathogens."
        ],
        "Which specific residues on the SARS-CoV-2 RBD does VHH60 target?": [
            "S351, S470-471, and S493-494",
            "E484, N501, and D614",
            "K417, L452, and T478",
            "F486, Q493, and Y505"
        ]
    }
}